HighTower Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.5M | Buy |
149,485
+2,101
| +1% | +$176K | 0.01% | 802 |
|
|
2026
Q1 | $11.8M | Buy |
147,384
+6,058
| +4% | +$499K | 0.01% | 810 |
|
|
2025
Q4 | $12M | Buy |
141,326
+7,214
| +5% | +$592K | 0.01% | 789 |
|
|
2025
Q3 | $10.4M | Buy |
134,112
+22,977
| +21% | +$1.8M | 0.01% | 830 |
|
|
2025
Q2 | $8.69M | Sell |
111,135
-30,695
| -22% | -$2.29M | 0.01% | 861 |
|
|
2025
Q1 | $10.3M | Buy |
141,830
+2,206
| +2% | +$158K | 0.01% | 754 |
|
|
2024
Q4 | $10.3M | Sell |
139,624
-255
| -0.2% | -$17.8K | 0.01% | 738 |
|
|
2024
Q3 | $9.21M | Sell |
139,879
-1,106
| -0.8% | -$80.4K | 0.01% | 786 |
|
|
2024
Q2 | $13M | Buy |
+140,985
| New | +$12.5M | 0.02% | 615 |
|
|
2024
Q1 | – | Sell |
-144,979
| Closed | -$11.1M | – | 3733 |
|
|
2023
Q4 | $11.1M | Sell |
144,979
-18,317
| -11% | -$1.27M | 0.02% | 668 |
|
|
2023
Q3 | $11.3M | Buy |
163,296
+6,344
| +4% | +$510K | 0.02% | 622 |
|
|
2023
Q2 | $14.8M | Buy |
156,952
+15,083
| +11% | +$1.31M | 0.03% | 528 |
|
|
2023
Q1 | $11.7M | Buy |
141,869
+699
| +0.5% | +$54.9K | 0.03% | 565 |
|
|
2022
Q4 | $10.5M | Sell |
141,170
-3,333
| -2% | -$257K | 0.02% | 591 |
|
|
2022
Q3 | $11.9M | Buy |
+144,503
| New | +$13.9M | 0.03% | 501 |
|
|
2022
Q2 | – | Sell |
-138,650
| Closed | -$16.3M | – | 3326 |
|
|
2022
Q1 | $16.3M | Sell |
138,650
-2,117
| -2% | -$237K | 0.04% | 448 |
|
|
2021
Q4 | $18.2M | Buy |
140,767
+3,535
| +3% | +$412K | 0.04% | 408 |
|
|
2021
Q3 | $15.5M | Buy |
137,232
+3,653
| +3% | +$417K | 0.04% | 397 |
|
|
2021
Q2 | $13.8M | Buy |
133,579
+8,391
| +7% | +$791K | 0.04% | 406 |
|
|
2021
Q1 | $10.5M | Buy |
+125,188
| New | +$10.6M | 0.03% | 467 |
|
|
2019
Q4 | – | Sell |
-100,113
| Closed | -$7.35M | – | 2430 |
|
|
2019
Q3 | $7.35M | Buy |
100,113
+306
| +0.3% | +$21.5K | 0.04% | 421 |
|
|
2019
Q2 | $6.15M | Sell |
99,807
-15,627
| -14% | -$945K | 0.04% | 487 |
|
|
2019
Q1 | $7.36M | Buy |
115,434
+26,652
| +30% | +$1.52M | 0.05% | 380 |
|
|
2018
Q4 | $4.53M | Sell |
88,782
-63,240
| -42% | -$3.2M | 0.03% | 488 |
|
|
2018
Q3 | $8.82M | Buy |
152,022
+1,311
| +0.9% | +$64.1K | 0.06% | 327 |
|
|
2018
Q2 | $7.31M | Sell |
150,711
-7,635
| -5% | -$356K | 0.06% | 367 |
|
|
2018
Q1 | $7.36M | Sell |
158,346
-72,042
| -31% | -$3.13M | 0.06% | 340 |
|
|
2017
Q4 | $8.66M | Sell |
230,388
-8,901
| -4% | -$327K | 0.07% | 298 |
|
|
2017
Q3 | $8.71M | Sell |
239,289
-7,197
| -3% | -$274K | 0.07% | 284 |
|
|
2017
Q2 | $9.71M | Buy |
246,486
+176,412
| +252% | +$6.44M | 0.09% | 254 |
|
|
2017
Q1 | $2.2M | Buy |
70,074
+1,335
| +2% | +$41.8K | 0.02% | 725 |
|
|
2016
Q4 | $2.15M | Buy |
68,739
+7,485
| +12% | +$243K | 0.02% | 677 |
|
|
2016
Q3 | $2.46M | Sell |
61,254
-10,422
| -15% | -$392K | 0.03% | 592 |
|
|
2016
Q2 | $2.38M | Buy |
71,676
+225
| +0.3% | +$7.7K | 0.03% | 579 |
|
|
2016
Q1 | $2.1M | Buy |
71,451
+31,926
| +81% | +$881K | 0.01% | 704 |
|
|
2015
Q4 | $1.04M | Buy |
+39,525
| New | +$1.03M | 0.01% | 951 |
|
|
2015
Q3 | – | Sell |
-116,892
| Closed | -$2.77M | – | 1886 |
|
|
2015
Q2 | $2.77M | Buy |
116,892
+8,388
| +8% | +$189K | 0.04% | 439 |
|
|
2015
Q1 | $2.58M | Buy |
108,504
+73,692
| +212% | +$1.65M | 0.04% | 507 |
|
|
2014
Q4 | $739K | Buy |
34,812
+20,670
| +146% | +$415K | 0.01% | 911 |
|
|
2014
Q3 | $241K | Sell |
14,142
-12,480
| -47% | -$197K | ﹤0.01% | 1292 |
|
|
2014
Q2 | $373K | Sell |
26,622
-155,682
| -85% | -$2.11M | 0.01% | 1155 |
|
|
2014
Q1 | $2.25M | Buy |
182,304
+118,674
| +187% | +$1.37M | 0.04% | 478 |
|
|
2013
Q4 | $697K | Buy |
63,630
+44,418
| +231% | +$501K | 0.01% | 833 |
|
|
2013
Q3 | $223K | Buy |
+19,212
| New | +$225K | 0.01% | 1128 |
|
Other funds holding EW
WT
HighTower Advisors's EW Position: Q2 2026 in Review
HighTower Advisors increased its Edwards Lifesciences (EW) stake by 1.4% in Q2 2026, buying an estimated $176K and bringing the position to 149,485 shares worth $13.5M. The position accounts for 0.01% of the portfolio, ranked #802.
HighTower Advisors first reported a position in EW in Q3 2013 and has held it in 44 quarters since. The position peaked at $18.2M in Q4 2021. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- HighTower Advisors held 149,485 shares of Edwards Lifesciences worth $13.5M as of Q2 2026.
- HighTower Advisors bought 2,101 Edwards Lifesciences shares in Q2 2026, an estimated $176K.
- Edwards Lifesciences made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #802 holding.
- HighTower Advisors first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 44 quarters since.
- HighTower Advisors's Edwards Lifesciences position peaked at $18.2M in Q4 2021.
- 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.